Last 12 months
Inside the activity.
0 purchase rows · 93 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 6 |
| Dec 2025 | 0 | 16 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 49 |
| Mar 2026 | 0 | 5 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 5 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 25, 2020 Filed Feb 26, 2020 21:37 UTC |
Silva Paul MSVP & Controller
|
SaleCommon Stock | 120 | $232.40 | $27,888.00 |
DisclosureSEC source: 0001209191-20-013037 · doc4.xml · nonDerivative · entry 4 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,472 F1 · kind: Transaction made pursuant to Mr. Silva's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $232.40 (range $232.37 to $232.44). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:37 UTC |
Silva Paul MSVP & Controller
|
SaleCommon Stock | 137 | $231.17 | $31,670.29 |
DisclosureSEC source: 0001209191-20-013037 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,592 F1 · kind: Transaction made pursuant to Mr. Silva's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $231.17 (range $230.73 to $231.47). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:37 UTC |
Silva Paul MSVP & Controller
|
SaleCommon Stock | 283 | $229.66 | $64,993.78 |
DisclosureSEC source: 0001209191-20-013037 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,729 F1 · kind: Transaction made pursuant to Mr. Silva's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $229.66 (range $229.20 to $230.14). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:39 UTC |
Tatsis OuraniaSVP, CRO
|
SaleCommon Stock | 240 | $237.81 | $57,074.40 |
DisclosureSEC source: 0001209191-20-013039 · doc4.xml · nonDerivative · entry 7 Tatsis Ourania · CIK 0001789815 · SVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,738 F1 · kind: Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $237.81 (range $237.24 to $238.18). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:39 UTC |
Tatsis OuraniaSVP, CRO
|
SaleCommon Stock | 160 | $235.39 | $37,662.40 |
DisclosureSEC source: 0001209191-20-013039 · doc4.xml · nonDerivative · entry 6 Tatsis Ourania · CIK 0001789815 · SVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,978 F1 · kind: Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $235.39 (range $235.33 to $235.44). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:39 UTC |
Tatsis OuraniaSVP, CRO
|
SaleCommon Stock | 240 | $234.43 | $56,263.20 |
DisclosureSEC source: 0001209191-20-013039 · doc4.xml · nonDerivative · entry 5 Tatsis Ourania · CIK 0001789815 · SVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,138 F1 · kind: Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $234.43 (range $234.14 to $234.89). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:39 UTC |
Tatsis OuraniaSVP, CRO
|
SaleCommon Stock | 80 | $232.43 | $18,594.40 |
DisclosureSEC source: 0001209191-20-013039 · doc4.xml · nonDerivative · entry 4 Tatsis Ourania · CIK 0001789815 · SVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,378 F1 · kind: Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:39 UTC |
Tatsis OuraniaSVP, CRO
|
SaleCommon Stock | 160 | $231.82 | $37,091.20 |
DisclosureSEC source: 0001209191-20-013039 · doc4.xml · nonDerivative · entry 3 Tatsis Ourania · CIK 0001789815 · SVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,458 F1 · kind: Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $231.82 (range $231.27 to $232.37). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:39 UTC |
Tatsis OuraniaSVP, CRO
|
SaleCommon Stock | 416 | $229.57 | $95,501.12 |
DisclosureSEC source: 0001209191-20-013039 · doc4.xml · nonDerivative · entry 2 Tatsis Ourania · CIK 0001789815 · SVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,618 F1 · kind: Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $229.57 (range $229.15 to $229.91). F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 21:29 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
Tax withholdingCommon Stock | 2,416 | $239.23 | $577,979.68 |
DisclosureSEC source: 0001209191-20-013016 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,930 Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 21:30 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
Tax withholdingCommon Stock | 2,898 | $239.23 | $693,288.54 |
DisclosureSEC source: 0001209191-20-013020 · doc4.xml · nonDerivative · entry 1 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,813 Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 21:31 UTC |
Bozic CarmenEVP, GMDA
|
Tax withholdingCommon Stock | 216 | $239.23 | $51,673.68 |
DisclosureSEC source: 0001209191-20-013023 · doc4.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP, GMDA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,302 Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 21:32 UTC |
Kewalramani ReshmaDirector · EVP and CMO
|
Tax withholdingCommon Stock | 2,898 | $239.23 | $693,288.54 |
DisclosureSEC source: 0001209191-20-013025 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,260 Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 21:34 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
Tax withholdingCommon Stock | 8,410 | $239.23 | $2,011,924.30 |
DisclosureSEC source: 0001209191-20-013029 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,131 Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 21:35 UTC |
Parini MichaelEVP, CL&AO
|
Tax withholdingCommon Stock | 2,416 | $239.23 | $577,979.68 |
DisclosureSEC source: 0001209191-20-013032 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,866 Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 21:36 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
Tax withholdingCommon Stock | 3,156 | $239.23 | $755,009.88 |
DisclosureSEC source: 0001209191-20-013034 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,291 Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 21:37 UTC |
Silva Paul MSVP & Controller
|
Tax withholdingCommon Stock | 864 | $239.23 | $206,694.72 |
DisclosureSEC source: 0001209191-20-013037 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,012 Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 21:39 UTC |
Tatsis OuraniaSVP, CRO
|
Tax withholdingCommon Stock | 1,036 | $239.23 | $247,842.28 |
DisclosureSEC source: 0001209191-20-013039 · doc4.xml · nonDerivative · entry 1 Tatsis Ourania · CIK 0001789815 · SVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,034 Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 21:40 UTC |
WAGNER CHARLES F JREVP and CFO
|
Tax withholdingCommon Stock | 542 | $239.23 | $129,662.66 |
DisclosureSEC source: 0001209191-20-013040 · doc4.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,274 Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:31 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 556 | $245.57 | $136,536.92 |
DisclosureSEC source: 0001209191-20-010534 · doc4.xml · nonDerivative · entry 6 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,346 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $245.57 (range $245.28 to $245.86). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:31 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 632 | $244.87 | $154,757.84 |
DisclosureSEC source: 0001209191-20-010534 · doc4.xml · nonDerivative · entry 5 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,902 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $244.87 (range $244.28 to $245.26). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:31 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 530 | $243.66 | $129,139.80 |
DisclosureSEC source: 0001209191-20-010534 · doc4.xml · nonDerivative · entry 4 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,534 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $243.66 (range $243.24 to $244.15). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:31 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 1,010 | $242.62 | $245,046.20 |
DisclosureSEC source: 0001209191-20-010534 · doc4.xml · nonDerivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,064 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $242.62 (range $242.24 to $243.21). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:31 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 400 | $241.80 | $96,720.00 |
DisclosureSEC source: 0001209191-20-010534 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,074 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $241.80 (range $241.24 to $242.23). F3 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:32 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
SaleCommon Stock | 377 | $245.76 | $92,651.52 |
DisclosureSEC source: 0001209191-20-010537 · doc4.xml · nonDerivative · entry 6 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,711 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $245.76 (range $245.54 to $245.90). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:32 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
SaleCommon Stock | 580 | $245.04 | $142,123.20 |
DisclosureSEC source: 0001209191-20-010537 · doc4.xml · nonDerivative · entry 5 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,088 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $245.04 (range $244.52 to $245.44). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:32 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
SaleCommon Stock | 400 | $243.76 | $97,504.00 |
DisclosureSEC source: 0001209191-20-010537 · doc4.xml · nonDerivative · entry 4 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,668 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $243.76 (range $243.45 to $244.43). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:32 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
SaleCommon Stock | 1,011 | $242.91 | $245,582.01 |
DisclosureSEC source: 0001209191-20-010537 · doc4.xml · nonDerivative · entry 3 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,068 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $242.08 (range $241.41 to $242.38). F4 · price: Open market sales reported on this line occurred at a weighted average price of $242.91 (range $242.43 to $243.42). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:32 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
SaleCommon Stock | 760 | $242.08 | $183,980.80 |
DisclosureSEC source: 0001209191-20-010537 · doc4.xml · nonDerivative · entry 2 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,079 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $242.08 (range $241.41 to $242.38). F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:33 UTC |
Kewalramani ReshmaDirector · EVP and CMO
|
SaleCommon Stock | 129 | $245.75 | $31,701.75 |
DisclosureSEC source: 0001209191-20-010541 · doc4.xml · nonDerivative · entry 6 Kewalramani Reshma · CIK 0001735944 · Director · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,158 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $245.75 (range $245.36 to $245.86). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:33 UTC |
Kewalramani ReshmaDirector · EVP and CMO
|
SaleCommon Stock | 260 | $244.94 | $63,684.40 |
DisclosureSEC source: 0001209191-20-010541 · doc4.xml · nonDerivative · entry 5 Kewalramani Reshma · CIK 0001735944 · Director · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,287 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $244.94 (range $244.36 to $245.32). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:33 UTC |
Kewalramani ReshmaDirector · EVP and CMO
|
SaleCommon Stock | 134 | $243.76 | $32,663.84 |
DisclosureSEC source: 0001209191-20-010541 · doc4.xml · nonDerivative · entry 4 Kewalramani Reshma · CIK 0001735944 · Director · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,547 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $243.76 (range $243.25 to $244.08). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:33 UTC |
Kewalramani ReshmaDirector · EVP and CMO
|
SaleCommon Stock | 540 | $242.62 | $131,014.80 |
DisclosureSEC source: 0001209191-20-010541 · doc4.xml · nonDerivative · entry 3 Kewalramani Reshma · CIK 0001735944 · Director · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,681 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $242.62 (range $242.25 to $243.21). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:33 UTC |
Kewalramani ReshmaDirector · EVP and CMO
|
SaleCommon Stock | 120 | $241.71 | $29,005.20 |
DisclosureSEC source: 0001209191-20-010541 · doc4.xml · nonDerivative · entry 2 Kewalramani Reshma · CIK 0001735944 · Director · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,221 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $241.71 (range $241.24 to $242.02). F3 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:35 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
SaleCommon Stock | 1,763 | $245.66 | $433,098.58 |
DisclosureSEC source: 0001209191-20-010544 · doc4.xml · nonDerivative · entry 6 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,541 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $245.66 (range $245.32 to $245.92). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:35 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
SaleCommon Stock | 2,030 | $244.87 | $497,086.10 |
DisclosureSEC source: 0001209191-20-010544 · doc4.xml · nonDerivative · entry 5 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,304 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $244.87 (range $244.30 to $245.26). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:35 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
SaleCommon Stock | 1,971 | $243.65 | $480,234.15 |
DisclosureSEC source: 0001209191-20-010544 · doc4.xml · nonDerivative · entry 4 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,334 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $243.65 (range $243.24 to $244.23). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:35 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
SaleCommon Stock | 4,241 | $242.61 | $1,028,909.01 |
DisclosureSEC source: 0001209191-20-010544 · doc4.xml · nonDerivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,305 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $242.61 (range $242.23 to $243.19). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:35 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
SaleCommon Stock | 1,680 | $241.78 | $406,190.40 |
DisclosureSEC source: 0001209191-20-010544 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,546 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $241.78 (range $241.20 to $242.19). F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:36 UTC |
Parini MichaelEVP, CL&AO
|
SaleCommon Stock | 694 | $245.52 | $170,390.88 |
DisclosureSEC source: 0001209191-20-010546 · doc4.xml · nonDerivative · entry 6 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,282 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $245.52 (range $245.26 to $245.86). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:36 UTC |
Parini MichaelEVP, CL&AO
|
SaleCommon Stock | 416 | $244.64 | $101,770.24 |
DisclosureSEC source: 0001209191-20-010546 · doc4.xml · nonDerivative · entry 5 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,976 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $244.64 (range $244.25 to $245.23). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:36 UTC |
Parini MichaelEVP, CL&AO
|
SaleCommon Stock | 560 | $243.59 | $136,410.40 |
DisclosureSEC source: 0001209191-20-010546 · doc4.xml · nonDerivative · entry 4 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,392 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $243.59 (range $243.24 to $244.15). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:36 UTC |
Parini MichaelEVP, CL&AO
|
SaleCommon Stock | 1,098 | $242.64 | $266,418.72 |
DisclosureSEC source: 0001209191-20-010546 · doc4.xml · nonDerivative · entry 3 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,952 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $242.64 (range $242.24 to $243.21). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:36 UTC |
Parini MichaelEVP, CL&AO
|
SaleCommon Stock | 360 | $241.75 | $87,030.00 |
DisclosureSEC source: 0001209191-20-010546 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,050 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $241.75 (range $241.24 to $242.23). F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:37 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 249 | $245.82 | $61,209.18 |
DisclosureSEC source: 0001209191-20-010550 · doc4.xml · nonDerivative · entry 6 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,447 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $245.82 (range $245.82 to $245.85). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:37 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 720 | $245.15 | $176,508.00 |
DisclosureSEC source: 0001209191-20-010550 · doc4.xml · nonDerivative · entry 5 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,696 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $245.15 (range $244.77 to $245.51). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:37 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 540 | $244.08 | $131,803.20 |
DisclosureSEC source: 0001209191-20-010550 · doc4.xml · nonDerivative · entry 4 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,416 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $244.08 (range $243.52 to $244.43). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:37 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 1,260 | $242.85 | $305,991.00 |
DisclosureSEC source: 0001209191-20-010550 · doc4.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,956 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $242.85 (range $242.45 to $243.32). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:37 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 720 | $242.04 | $174,268.80 |
DisclosureSEC source: 0001209191-20-010550 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,216 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $242.04 (range $241.43 to $242.40). F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:38 UTC |
Silva Paul MSVP & Controller
|
SaleCommon Stock | 202 | $245.74 | $49,639.48 |
DisclosureSEC source: 0001209191-20-010554 · doc4.xml · nonDerivative · entry 6 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,876 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $245.74 (range $245.55 to $245.86.) Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.